Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (Nasdaq: TSHA) announced on March 2, 2026 that its Compensation Committee granted inducement awards under the 2023 Inducement Plan for two new employees.
Taysha Gene Therapies (Nasdaq: TSHA) announced on March 2, 2026 that its Compensation Committee granted inducement awards under the 2023 Inducement Plan for two new employees.
The awards: 156,870 RSUs vesting in four equal annual installments, and a stock option to purchase 134,460 shares at an exercise price of $4.53 (10-year term) with four-year vesting.
Grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and vesting is subject to continued service.
On Mar 6, the day this news came out, TSHA closed 1.78% above the previous close.
Data tracked by StockTitan Argus for the Mar 6 session.
Market Context
This announcement details a standard inducement equity package for a new hire, including 156,870 RSU...
Analysis
This announcement details a standard inducement equity package for a new hire, including 156,870 RSUs and options on 134,460 shares at a $4.53 exercise price, vesting over four years. It follows similar grants disclosed in recent months under the 2023 Inducement Plan. In context of prior news, operational progress on TSHA-102 and forthcoming clinical and financial updates remain the primary fundamental catalysts to watch for this company.
Key Figures
RSU grant size:156,870 sharesStock option grant:134,460 sharesExercise price:$4.53+4 more
RSU grant size
156,870 shares
New employee inducement RSUs under 2023 Inducement Plan
Stock option grant
134,460 shares
New employee stock option under 2023 Inducement Plan
Exercise price
$4.53
Option strike equal to closing price on March 2, 2026
Option term
10 years
Maximum life of the new employee stock option
RSU vesting schedule
4 annual installments
Equal annual vesting beginning first anniversary of vesting start
Initial option vest
25%
Vests on first anniversary of vesting commencement date
Remaining option vest
75% over 36 months
Monthly vesting after first anniversary, subject to continued service
Announcement of timing and access details for Q3 2025 earnings call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adeno-associated virus, gene therapies, central nervous system, restricted stock units, +4 more
8 terms
adeno-associated virusmedical
"advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic"
Adeno-associated virus (AAV) is a naturally occurring, small virus that researchers use as a safe carrier to deliver corrective genes into human cells, much like a specialized delivery van transporting instructions to a malfunctioning machine. It matters to investors because AAV-based therapies drive large development costs, unique manufacturing and regulatory risks, and the potential for high-value, one-time treatments that can significantly affect a biotech company’s future revenue and valuation.
gene therapiesmedical
"AAV)-based gene therapies for severe monogenic diseases of the central"
Gene therapies are medical treatments that change or replace a person’s genetic instructions to fix or counteract a disease, using biological delivery methods to get the new material into cells — like repairing or swapping pages in a faulty instruction manual. They matter to investors because they can offer one-time or long-lasting cures with large market potential, but carry high development costs, regulatory scrutiny and manufacturing challenges that make outcomes binary and investment risky.
central nervous systemmedical
"diseases of the central nervous system (CNS), today announced that, on"
The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.
restricted stock unitsfinancial
"granted one new employee restricted stock units (RSUs) representing 156,870 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUsfinancial
"restricted stock units (RSUs) representing 156,870 shares of the Company’s"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
stock optionfinancial
"and an option to purchase 134,460 shares of the Company's common stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise pricefinancial
"The stock option has an exercise price of $4.53 which is equal"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Nasdaq Listing Rule 5635(c)(4)regulatory
"as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 2, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 156,870 shares of the Company’s common stock and an option to purchase 134,460 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date. The stock option has an exercise price of $4.53 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.
About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact: Hayleigh Collins Senior Director, Corporate Communications and Investor Relations Taysha Gene Therapies, Inc. hcollins@tayshagtx.com
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What exactly did Taysha (TSHA) grant under the March 2, 2026 inducement award?
Taysha granted 156,870 restricted stock units (RSUs) and a stock option for 134,460 shares. According to Taysha, the RSUs vest in four equal annual installments and the option vests over four years with a 10-year exercise term.
What is the exercise price and term of the stock option granted by Taysha (TSHA)?
The stock option exercise price is $4.53 and the term is 10 years. According to Taysha, $4.53 equals the closing price on the grant date and the option vests 25% after one year, then monthly over 36 months.
How do the RSU vesting terms work for the inducement grant at Taysha (TSHA)?
The RSUs vest in four equal annual installments beginning one year after the vesting commencement date. According to Taysha, vesting is conditioned on each employee's continued service through each annual vesting date.
Under which plan and Nasdaq rule were Taysha's (TSHA) inducement awards granted?
The awards were granted under the 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4). According to Taysha, the grants were intended as inducements material to the individuals entering employment.
Will Taysha (TSHA) shareholders experience immediate dilution from the March 2026 inducement grants?
The grants create potential future dilution if options are exercised and RSUs vest and settle. According to Taysha, the awards total 291,330 shares of potential issuance, subject to vesting and any future exercises.
